Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMDGlobeNewsWire • 03/22/24
All You Need to Know About Oncobiologics (OTLK) Rating Upgrade to BuyZacks Investment Research • 03/21/24
Outlook Therapeutics® Announces Closing of Private Placement of up to $159 MillionGlobeNewsWire • 03/18/24
Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock SplitGlobeNewsWire • 03/12/24
Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate UpdateGlobeNewsWire • 02/14/24
Outlook Therapeutics® Receives FDA Agreement Under Special Protocol Assessment (SPA) for 90 Day Non-Inferiority Study, NORSE EIGHT, and Announces Private Placement of Up to $172 Million to Advance ONS-5010GlobeNewsWire • 01/23/24
OTLK FINAL DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important January 2 Deadline in Securities Class Action - OTLKPRNewsWire • 01/02/24
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Outlook Therapeutics, Inc.(OTLK) Investors of a Class Action Lawsuit and Upcoming DeadlinePRNewsWire • 01/02/24
OTLK DEADLINE TOMORROW: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important January 2 Deadline in Securities Class Action – OTLKBusiness Wire • 01/01/24
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Outlook Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - OTLKPRNewsWire • 12/28/23
OTLK Investors Have Opportunity to Lead Outlook Therapeutics, Inc. Securities Fraud LawsuitPRNewsWire • 12/28/23
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Outlook Therapeutics, Inc. (OTLK)Business Wire • 12/28/23
OUTLOOK INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Outlook To Contact Him Directly To Discuss Their OptionsPRNewsWire • 12/28/23
INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Outlook Therapeutics, Inc. with Losses In Excess of $100,000 to Contact the FirmAccesswire • 12/27/23
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Outlook Therapeutics, Inc. Investors With Losses to Secure Counsel Before Important January 2 Deadline in Securities Class Action - OTLKPRNewsWire • 12/26/23
Outlook Therapeutics® Reports Financial Results for Fiscal Year 2023 and Reiterates ONS-5010 Clinical and Regulatory Path Forward in the U.S. and EUGlobeNewsWire • 12/22/23
IMPORTANT DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Outlook Therapeutics, Inc. with Losses In Excess of $500,000 to Contact the FirmAccesswire • 12/22/23
Outlook Therapeutics® Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ONS-5010GlobeNewsWire • 12/19/23
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Outlook Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 2, 2024 - (NASDAQ: OTLK)PRNewsWire • 12/18/23
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - OTLKPRNewsWire • 12/17/23
ROSEN, A RANKED AND LEADING FIRM, Encourages Outlook Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - OTLKPRNewsWire • 12/11/23